Implementation Grant Funding Opportunity Open
IMPORTANT: The grant program operates on a rolling basis and applications may be submitted at any time, with quarterly reviews.
Learn More
Implementation Grant Funding Opportunity Open
Qualifying* small and medium-sized US manufacturers, that received IAC or Combined Heat and Power Technical Assistance Partnership assessments between 2018 and 2024, can now apply for grants for implementation of assessment recommendations up 50% of qualifying* project costs with a maximum of $300,000 per manufacturer.
IMPORTANT: The grant program now operates on a rolling basis and applications may be submitted at any time through the year, with quarterly reviews.
*See Full Grant Solicitation for full qualification and selection details.
220
matching assessments| SIC | 283 | Drugs |
|---|
| ID | Year | Products | Reccs | Plant Energy Costs | Recommended Savings |
|---|---|---|---|---|---|
| SF0623 | 2024 |
SF0623 | 2024
Synthetic Peptides
|
5 | $186,119 | $16,345 |
| UU0255 | 2024 |
UU0255 | 2024
Vitamins and supplements
|
8 | $538,876 | $99,033 |
| MI0445 | 2024 |
MI0445 | 2024
Pharmaceuticals
|
8 | $3,373,335 | $837,486 |
| MI0443 | 2024 |
MI0443 | 2024
Soft Gels
|
8 | $422,335 | $64,808 |
| AS0579 | 2024 |
AS0579 | 2024
Nutraceuticals
|
7 | $169,274 | $114,992 |
| SU0551 | 2024 |
SU0551 | 2024
Biologics Drug Substance
|
11 | $2,735,409 | $116,364 |
| MI0439 | 2024 |
MI0439 | 2024
Pharmaceuticals
|
6 | $1,088,753 | $661,504 |
| SU0548 | 2024 |
SU0548 | 2024
Biologics Drug Substance
|
10 | $2,278,153 | $217,454 |
| UW2402 | 2024 |
UW2402 | 2024
Pharmaceutical Preparation Manufacturing
|
8 | $395,527 | $177,482 |
| MI0436 | 2023 |
MI0436 | 2023
Vitamins, Supplements
|
9 | $221,279 | $3,202,254 |
| AS0566 | 2023 |
AS0566 | 2023
Dietary Supplements
|
6 | $100,291 | $33,443 |
| OR0779 | 2023 |
OR0779 | 2023
Phase I/II clinical trial materials, Spray-dried drugs, Tablets/capsules
|
4 | $107,472 | $54,364 |
| UU0221 | 2023 |
UU0221 | 2023
Nutrition supplement
|
7 | $117,116 | $48,791 |
| LE0546 | 2023 |
LE0546 | 2023
Generic Drugs
|
9 | $2,388,272 | $170,476 |
| SD0629 | 2023 |
SD0629 | 2023
Processed Plasma
|
5 | $513,576 | $73,378 |
| SD0626 | 2023 |
SD0626 | 2023
Antibodies, Cell Therapies
|
6 | $1,515,916 | $238,831 |
| SD0625 | 2023 |
SD0625 | 2023
Antibodies, Cell Therapies
|
5 | $562,294 | $112,789 |
| CC0011 | 2022 |
CC0011 | 2022
Active Pharmaceutical Ingredients
|
5 | $548,754 | $20,182 |
| LE0539 | 2023 |
LE0539 | 2023
Medical Diagnostics solutions
|
4 | $726,028 | $43,977 |
| UD1038 | 2022 |
UD1038 | 2022
Pharmaceuticals
|
7 | $1,083,858 | $90,960 |
| MI0395 | 2021 |
MI0395 | 2021
Pharma Tablets
|
7 | $608,200 | $54,033 |
| NL0061 | 2022 |
NL0061 | 2022
OTC Medicine
|
8 | $1,755,128 | $34,197 |
| NC0654 | 2020 |
NC0654 | 2020
Pharmaceutical preparations
|
5 | $4,501,017 | $1,453,635 |
| UD1024 | 2020 |
UD1024 | 2020
Vivitrol, Aristada, Risperdal Consta, and Polymer
|
11 | $2,375,024 | $1,139,082 |
| IP0141 | 2020 |
IP0141 | 2020
Pharmaceuticals
|
5 | $348,318 | $20,579 |